Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. GPX4 compound 30
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. GPX4 compound 30: sourced facts only. name: "Enzyme activity assays demonstrated that compound 30 significantly inhibited GPX4 enzymatic activity." [PMID:40795665]; target: "Enzyme activity assays demonstrated that compound 30 significantly inhibited GPX4 enzymatic activity." [PMID:40795665]; developer: "State Key Laboratory of Natural Medicines, Basic Medical Research Innovation Center for Anti-Cancer Drugs, Ministry of Education, China Pharmaceutical University, Nanjing 210009, People's Republic of China." [PMID:40795665]; stage: "The results of the cytotoxicity test showed that compound 30 significantly inhibited the proliferation of colon cancer cells (HCT-116 and HT-29)." [PMID:40795665]
02
Targets
GPX4 (Glutathione peroxidase 4)
Beyond the preview
Go deeper on China Pharma Univ. GPX4 compound 30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. GPX4 compound 30.